Lotus Eye Hospital Institute Ltd vs Sharma East India Hosp And Medical Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Lotus Eye Hospital & Institute Ltd is ₹ 106.5 as of 30 Oct 15:30 . The P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 55.9 on March 2021 to 2533 on March 2026 . This represents a CAGR of 88.83% over 6 yearsThe P/E Ratio of Sharma East India Hosp and Medical Research Ltd changed from 24.9 on March 2025 to 34.6 on March 2026 . This represents a CAGR of 17.88% over 2 years The Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 87.14 crore on March 2021 to ₹ 210.77 crore on March 2026 . This represents a CAGR of 15.86% over 6 yearsThe Market Cap of Sharma East India Hosp and Medical Research Ltd changed from ₹ 24.42 crore on March 2025 to ₹ 33.94 crore on March 2026 . This represents a CAGR of 17.89% over 2 years The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 17.27 crore as compare to the Mar '26 revenue of ₹ 14.09 crore. This represent the growth of 22.57% The revenue of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 10.8 crore as compare to the Mar '26 revenue of ₹ 7.49 crore. This represent the growth of 44.19% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 3.15 crore as compare to the Mar '26 ebitda of ₹ 0.95 crore. This represent the growth of 231.58% The ebitda of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 0.9 crore as compare to the Mar '26 ebitda of ₹ 1.03 crore. This represent the decline of -12.62% The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0.62 crore to ₹ 0.61 crore over 9 quarters. This represents a CAGR of -0.72% The net profit of Sharma East India Hosp and Medical Research Ltd changed from ₹ 0.25 crore to ₹ 0.26 crore over 9 quarters. This represents a CAGR of 1.76% The Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Sharma East India Hosp and Medical Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013. Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy. Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.

About Sharma East India Hosp and Medical Research Ltd

Sharma East India Hospitals & Medical Research Limited was incorporated on November 16, 1989.
The Company is engaged in providing medical and healthcare services and real estate services and is presently running a multi-specialty hospital in the name of 'Jaipur Hospital' at Lal Kothi, at Rajasthan since 1989. As far as the achievements of the Company are concerned, the first assessment of the Company was conducted by National Accreditation Board for Hospitals and Health Care Providers (NABH), NABH accreditation system is one of the methods for commitment to quality enhancement throughout whole of the health care system in India.
It involves all professional and service groups to ensure that high quality in health care is achieved, while minimizing the inherent risks associated with modern health care delivery.

FAQs for the comparison of Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd

Which company has a larger market capitalization, Lotus Eye Hospital & Institute Ltd or Sharma East India Hosp and Medical Research Ltd?

Market cap of Lotus Eye Hospital & Institute Ltd is 221 Cr while Market cap of Sharma East India Hosp and Medical Research Ltd is 26 Cr

What are the key factors driving the stock performance of Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd?

The stock performance of Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd?

As of November 1, 2026, the Lotus Eye Hospital & Institute Ltd stock price is INR ₹106.5. On the other hand, Sharma East India Hosp and Medical Research Ltd stock price is INR ₹80.0.

How do dividend payouts of Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd compare?

To compare the dividend payouts of Lotus Eye Hospital & Institute Ltd and Sharma East India Hosp and Medical Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.